Tiger Brokers

Gain Therapeutics FY2025 net loss per share narrows 31.46% to $0.61; cash, cash equivalents and marketable securities climb more than doubled to $20.8 million

Reuters
Mar 26
Gain <a href="https://laohu8.com/S/LENZ">Therapeutics</a> FY2025 net loss per share narrows 31.46% to $0.61; cash, cash equivalents and marketable securities climb more than doubled to $20.8 million
  • Gain Therapeutics published a financial results press release for the fourth quarter and year ended December 31, 2025, alongside a corporate update.
  • Net loss for the year was USD 20.2 million, or USD 0.61 per share, compared with a 1.2% narrower net loss of USD 20.4 million a year earlier.
  • R&D expenses fell 5.4% to USD 10.2 million, primarily due to optimization of pipeline costs, partially offset by unfavorable foreign exchange translation.
  • G&A expenses decreased 11.1% to USD 8.5 million, mainly from lower stock-based compensation and legal fees, partially offset by higher personnel costs and unfavorable foreign exchange translation.
  • Cash, cash equivalents and marketable securities were USD 20.8 million at year-end, and the company said it expects FDA clearance of its IND submission in 2Q26 and plans to start a Phase 2 trial of GT-02287 in 3Q26.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603260700PRIMZONEFULLFEED9678994) on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10